Observational studyBMC pediatrics2021
Serum HMGB1 level is correlated with serum I-FABP level in neonatal patients with necrotizing enterocolitis.
Observational study in BMC pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The value of intestinal fatty acid binding protein as a biomarker for the diagnosis of necrotizing enterocolitis in preterm infants: a meta-analysis.BMC pediatrics · 2025Pooled it
- NINJ1 as a novel biomarker of intestinal injury in necrotizing enterocolitis.BMC pediatrics · 2026Observational
- The role of NLRP3 inflammasome in necrotizing enterocolitis.Pediatric research · 2026Review
- Gastrointestinal insufficiency is a risk factor for severely burned patients: a case-control study among 185 victims in Kunshan explosion.BMC gastroenterology · 2025Article
- The role of fecal short-chain fatty acids in neonatal necrotizing enterocolitis.Translational pediatrics · 2025Article
- Adoption value of serum hematological inflammatory markers in early diagnosis of necrotising enterocolitis.Journal of medical biochemistry · 2025Article
- Anti-DAMP therapies for acute inflammation.Frontiers in immunology · 2025Review
- Modulation of intestinal TLR4 expression in infants with neonatal opioid withdrawal syndrome.Journal of perinatology : official journal of the California Perinatal Association · 2024Article
- Diagnostic significance of serum levels of serum amyloid A, procalcitonin, and high-mobility group box 1 in identifying necrotising enterocolitis in newborns.World journal of gastrointestinal surgery · 2024Article
- I-FABP protein/mRNA and IL-6 as biomarkers of intestinal barrier dysfunction in neonates with necrotizing enterocolitis and SPF BALB/c mouse models.The Journal of international medical research · 2024Article
- Chromatin as alarmins in necrotizing enterocolitis.Frontiers in immunology · 2024Review
- Predictive value of serum markers in the operation evaluation of neonatal necrotizing enterocolitis.Translational pediatrics · 2023Article
- New insights into intestinal macrophages in necrotizing enterocolitis: the multi-functional role and promising therapeutic application.Frontiers in immunology · 2023Review
- Gut microbiota and short-chain fatty acids may be new biomarkers for predicting neonatal necrotizing enterocolitis: A pilot study.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to investigate clinical significance of HMGB1 in neonatal patients with necrotizing enterocolitis (NEC).
methodsThis observational study enrolled a total of 106 stage II-III NEC neonatal patients, who were admitted in our hospital from March 2014 to March 2019. In addition, 99 suspected NEC patients and 200 healthy controls were included. The serum levels of HMGB1, I-FABP, and inflammatory factors CRP, IL-1β, IL-6 and TNF-α were determined by enzyme-linked immunosorbent assay (ELISA). Then, the demographic data and clinical characteristics of all patients were collected. Statistical analysis was conducted to determine the correlation between HMGB1 and the clinical characteristics.
resultsNo significant difference was found in the basic characteristics of NEC patients and healthy controls, except for birth weight and gestational age. The expression levels of HMGB1, I-FABP, and inflammatory factors IL-1β, IL-6 and TNF-α were significantly higher in NEC patients, when compared to healthy controls. The serum levels of HMGB1, I-FABP, IL-1β and IL-6 markedly increased in stage II-III NEC patients, when compared to stage I NEC patients. The Pearson's analysis revealed a positive correlation between HMGB1 and I-FABP, HMGB1 and IL-1β, and HMGB1 and IL-6. The ROC curve revealed that both HMGB1 and I-FABP can potentially be used as diagnostic factors for NEC. The logistic multivariate regression revealed that I-FABP, IL-1β and IL-6 are independent risk factors for mortality in neonatal NEC patients.
conclusionsSerum HMGB1 levels are upregulated in neonatal NEC patients, and these are correlated with the patient's prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.